Access to the abortion pill mifepristone would revert to older rules
This bill would undo changes the Food and Drug Administration (FDA) made in January 2023 to how the abortion pill mifepristone can be prescribed and dispensed. If passed, it would make it harder for people to get the medication, returning to earlier requirements for healthcare providers. The bill also blocks the FDA from making similar changes in the future.
Today, the Food and Drug Administration's (FDA) January 2023 modifications to the rules for mifepristone are in effect, which generally made it easier to access the medication. If this bill becomes law, those January 2023 modifications would be canceled, and the rules for mifepristone would revert to how they were before that date, potentially making it harder to obtain. The FDA and HHS would also be blocked from making similar changes in the future.
HR 679 · 119th Congress · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
1 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.